Morning Market Losers

Model N MODN dropped 31.57% to $10.08 on downbeat FY14 forecast. JP Morgan downgraded the stock from “overweight” to “neutral.” Neurocrine Biosciences NBIX plummeted 29.82% to $11.72 after the company reported Phase IIb results Of VMAT2 Inhibitor NBI-98854 for treatment of tardive dyskinesia. ChemoCentryx CCXI dropped 23.97% to $6.28 after the company announced top-line interim results for CCX140 in an ongoing Phase II trial. HD Supply Holdings HDS dropped 11.59% to $21.88 on Q2 results.